Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode, EraGen Reach MDx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Applied BioCode is providing EraGen Biosciences access to its Barcoded Magnetic Bead technology and the CE-marked BioCode -1000 system under a partnership and licensing agreement announced today.

The technology provides a solution for development and clinical laboratory use of multiplexed infectious disease and genetic tests, Applied BioCode said. Its President, Winston Ho, added in a statement that the combination of his firm's technology with EraGen's patented chemistry is expected to result in a "powerful testing platform for clinical laboratories."

Financial and other terms of the deal were not disclosed.

"We look forward to commercializing molecular diagnostics that address not only customers needing real-time molecular testing, but also those in the growing segment that need highly multiplexed in vitro diagnostics," Irene Hrusovsky, chairperson and chief executive of EraGen, added.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.